Eberechukwu Onukwugha3, Nicholas J Petrelli4, Kathleen M Castro4, James F Gardner4, Jinani Jayasekera4, Olga Goloubeva4, Ming T Tan4, Erica J McNamara4, Howard A Zaren4, Thomas Asfeldt4, James D Bearden4, Andrew L Salner4, Mark J Krasna4, Irene Prabhu Das4, Steve B Clauser4, Eberechukwu Onukwugha3, Nicholas J Petrelli4, Kathleen M Castro4, James F Gardner4, Jinani Jayasekera4, Olga Goloubeva4, Ming T Tan4, Erica J McNamara4, Howard A Zaren4, Thomas Asfeldt4, James D Bearden4, Andrew L Salner4, Mark J Krasna4, Irene Prabhu Das4, Steve B Clauser4. 1. University of Maryland, Baltimore, Helen F. Graham Cancer Center at Christiana Care, National Cancer Institute, American College of Surgeons, Nancy N. and J.C. Lewis Cancer and Research Pavilion, at St. Joseph's/Candler Hospital System and Georgia Regents University, Sanford Health, Spartanburg Regional Hospital, Hartford Hospital, Meridian Health, Inc., Patient Centered Outcomes Research Institute eonukwug@rx.umaryland.edu. 2. University of Maryland, Baltimore, Helen F. Graham Cancer Center at Christiana Care, National Cancer Institute, American College of Surgeons, Nancy N. and J.C. Lewis Cancer and Research Pavilion, at St. Joseph's/Candler Hospital System and Georgia Regents University, Sanford Health, Spartanburg Regional Hospital, Hartford Hospital, Meridian Health, Inc., Patient Centered Outcomes Research Institute. 3. University of Maryland School of Pharmacy; University of Maryland School of Medicine, Baltimore; National Cancer Institute, Rockville; Cancer Institute at St Joseph Medical Center, Towson, MD; Helen F. Graham Cancer Center, Christiana Care, Wilmington, DE; American College of Surgeons, Chicago, IL; Nancy N. and J.C. Lewis Cancer and Research Pavilion, St Joseph's/Candler Hospital System, Savannah, GA; Sanford Cancer Center, Sioux Falls, SD; Gibbs Cancer Center and Research Institute, Spartanburg, SC; and Helen and Harry Gray Cancer Center, Hartford Hospital, Hartford, CT eonukwug@rx.umaryland.edu. 4. University of Maryland School of Pharmacy; University of Maryland School of Medicine, Baltimore; National Cancer Institute, Rockville; Cancer Institute at St Joseph Medical Center, Towson, MD; Helen F. Graham Cancer Center, Christiana Care, Wilmington, DE; American College of Surgeons, Chicago, IL; Nancy N. and J.C. Lewis Cancer and Research Pavilion, St Joseph's/Candler Hospital System, Savannah, GA; Sanford Cancer Center, Sioux Falls, SD; Gibbs Cancer Center and Research Institute, Spartanburg, SC; and Helen and Harry Gray Cancer Center, Hartford Hospital, Hartford, CT.
Abstract
PURPOSE: The role of multidisciplinary care (MDC) on cancer care processes is not fully understood. We investigated the impact of MDC on the processes of care at cancer centers within the National Cancer Institute Community Cancer Centers Program (NCCCP). METHODS: The study used data from patients diagnosed with stage IIB to III rectal cancer, stage III colon cancer, and stage III non–small-cell lung cancer at 14 NCCCP cancer centers from 2007 to 2012. We used an MDC development assessment tool—with levels ranging from evolving MDC (low) to achieving excellence (high)—to measure the level of MDC implementation in seven MDC areas, such as case planning and physician engagement. Descriptive statistics and cluster-adjusted regression models quantified the association between MDC implementation and processes of care, including time from diagnosis to treatment receipt. RESULTS: A total of 1,079 patients were examined. Compared with patients with colon cancer treated at cancer centers reporting low MDC scores, time to treatment receipt was shorter for patients with colon cancer treated at cancer centers reporting high or moderate MDC scores for physician engagement (hazard ratio [HR] for high physician engagement, 2.66; 95% CI, 1.70 to 4.17; HR for moderate physician engagement, 1.50; 95% CI, 1.19 to 1.89) and longer for patients with colon cancer treated at cancer centers reporting high 2MDC scores for case planning (HR, 0.65; 95% CI, 0.49 to 0.85). Results for patients with rectal cancer were qualitatively similar, and there was no statistically significant difference among patients with lung cancer. CONCLUSION: MDC implementation level was associated with processes of care, and direction of association varied across MDC assessment areas.
PURPOSE: The role of multidisciplinary care (MDC) on cancer care processes is not fully understood. We investigated the impact of MDC on the processes of care at cancer centers within the National Cancer Institute Community Cancer Centers Program (NCCCP). METHODS: The study used data from patients diagnosed with stage IIB to III rectal cancer, stage III colon cancer, and stage III non–small-cell lung cancer at 14 NCCCP cancer centers from 2007 to 2012. We used an MDC development assessment tool—with levels ranging from evolving MDC (low) to achieving excellence (high)—to measure the level of MDC implementation in seven MDC areas, such as case planning and physician engagement. Descriptive statistics and cluster-adjusted regression models quantified the association between MDC implementation and processes of care, including time from diagnosis to treatment receipt. RESULTS: A total of 1,079 patients were examined. Compared with patients with colon cancer treated at cancer centers reporting low MDC scores, time to treatment receipt was shorter for patients with colon cancer treated at cancer centers reporting high or moderate MDC scores for physician engagement (hazard ratio [HR] for high physician engagement, 2.66; 95% CI, 1.70 to 4.17; HR for moderate physician engagement, 1.50; 95% CI, 1.19 to 1.89) and longer for patients with colon cancer treated at cancer centers reporting high 2MDC scores for case planning (HR, 0.65; 95% CI, 0.49 to 0.85). Results for patients with rectal cancer were qualitatively similar, and there was no statistically significant difference among patients with lung cancer. CONCLUSION: MDC implementation level was associated with processes of care, and direction of association varied across MDC assessment areas.
Authors: Sonja Eaker; Paul W Dickman; Vivan Hellström; Matthew M Zack; Johan Ahlgren; Lars Holmberg Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-12 Impact factor: 4.254
Authors: Leonard G Gomella; Jianqing Lin; Jean Hoffman-Censits; Patricia Dugan; Fran Guiles; Costas D Lallas; Jaspreet Singh; Peter McCue; Timothy Showalter; Richard K Valicenti; Adam Dicker; Edouard J Trabulsi Journal: J Oncol Pract Date: 2010-11 Impact factor: 3.840
Authors: Richard K Freeman; Jaclyn M Van Woerkom; Amy Vyverberg; Anthony J Ascioti Journal: Eur J Cardiothorac Surg Date: 2010-03-04 Impact factor: 4.191
Authors: Benjamin W Lamb; James S A Green; Jonathan Benn; Katrina F Brown; Charles A Vincent; Nick Sevdalis Journal: J Am Coll Surg Date: 2013-07-25 Impact factor: 6.113
Authors: Ashley N Krepline; Lindsay Bliss; Jennifer Geurts; Idayat Akinola; Kathleen K Christians; Ben George; Paul S Ritch; William A Hall; Beth A Erickson; Douglas B Evans; Susan Tsai Journal: J Gastrointest Surg Date: 2019-11-19 Impact factor: 3.452